Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.
Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions.
Key facts
Unless stated all financials at 30 September 2025
£227m
Value of clinical portfolio
11
Number of clinical trials
9
Portfolio Company Board seats
Our clinical stage portfolio companies
Latest clinical stage portfolio insights
The clinical stage portfolio pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
